Psilocybin for PTSD Treatment: What Current Research Shows

Post-traumatic stress disorder (PTSD) can be debilitating, with symptoms that persist long after a traumatic event. While traditional treatments such as antidepressants and trauma-focused therapy can be effective, many individuals continue to experience ongoing distress, impaired functioning, and reduced quality of life.

In recent years, researchers have begun exploring new approaches to care, including psychedelic-assisted therapy. One emerging area of interest is COMP360 psilocybin, a pharmaceutical-grade formulation that has now been studied in individuals with PTSD for the first time in a clinical trial setting.

Inside the Psilocybin PTSD Clinical Trial

This Phase 2 clinical trial included 22 adults with clinically confirmed PTSD, representing a range of traumatic experiences, including interpersonal trauma, loss, and combat or warzone exposure.

Each participant received a single 25 mg dose of COMP360 psilocybin, administered in a controlled clinical setting with trained therapists providing preparation and integration support. Outcomes were monitored over a 12-week period.

Psilocybin Safety and Tolerability in PTSD Treatment

Overall, the treatment was found to be well-tolerated in a supervised clinical environment.

Participants commonly experienced temporary effects such as:

• Headache
• Nausea
• Fatigue
• Emotional release, including crying

These effects typically occurred on the day of treatment and resolved within 24 hours.

A small number of participants experienced more intense but short-lived effects, including perceptual changes or physical sensations. Importantly:

• No serious adverse events were reported
• No participants discontinued the study due to side effects

Two individuals reported brief periods of suicidal thinking, both of whom had a prior history. These experiences resolved and highlight the importance of structured support and clinical monitoring in this type of therapy.

PTSD Symptom Improvement After Psilocybin Therapy

One of the most notable outcomes of the study was the degree and speed of improvement in PTSD symptoms. To better understand these results, it helps to look at how changes are measured.

• Clinician-rated PTSD severity (CAPS-5): This is a standardized tool used by clinicians to assess how severe PTSD symptoms are. In this study, scores decreased by nearly 30 points within four weeks. In practical terms, this reflects a substantial reduction in symptom burden, often including fewer intrusive memories, less emotional distress, and improved ability to regulate reactions. More than 80% of participants improved enough to be considered “responders,” meaning their symptoms decreased in a clinically meaningful way.
• Patient-reported symptoms (PCL-5): Participants also reported how they felt using their own assessments. Improvements were seen as early as the day after treatment and remained consistent throughout the 12-week follow-up period.
• Functioning and quality of life: Beyond symptom scores, participants described noticeable improvements in daily life. This included better ability to manage responsibilities, improved emotional stability, and a greater sense of overall well-being.

Together, these findings suggest that psilocybin-assisted therapy may support both measurable symptom relief and meaningful improvements in everyday functioning.

How the Psychedelic Experience Affects PTSD Outcomes

The study also explored how the nature of the psychedelic experience itself related to outcomes.

Participants who reported stronger feelings of emotional connection, openness, and a sense of unity—referred to in research as “oceanic boundlessness”—tended to experience greater symptom improvement.

This suggests that the quality and structure of the therapeutic experience, not just the medication alone, may play an important role in outcomes. It reinforces the importance of preparation, guidance, and integration as part of the overall treatment process.

The Future of Psilocybin Therapy for PTSD

These findings point in a meaningful direction. A single, guided psilocybin session was associated with rapid improvements that extended over several months, along with a favorable safety profile in a controlled setting.

What is becoming increasingly clear is that innovative, integrative approaches like this are expanding what’s possible in mental health care. For individuals who have not found relief through traditional treatments, this growing area of research offers a promising pathway toward healing, resilience, and improved quality of life.

Read the Study: McGowan NM, Rucker JJ, Yehuda R, et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. Journal of Psychopharmacology. 2025;0(0). doi:10.1177/02698811251362390